BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The company AstraZeneca, UK Limited submitted on 4 February 2003 an application for Marketing 
Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for 
Faslodex,  through  the  centralised  procedure.  After  agreement  by  the  CPMP  on  21  September  2000, 
this  medicinal  product  has  been  referred  to  Part  B  of  the  Annex  to  Council  Regulation  No  (EEC) 
2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr. Salmonson 
Co-Rapporteur:  Dr. Toivonen 
Scientific Advice: 
The  applicant  received  Scientific  Advice  from  the  CPMP  on  17  December  1997.  The  Scientific 
Advice pertained to clinical aspects of the dossier.  
Licensing status: 
Faslodex has been given a Marketing Authorisation in USA on 25 April 2002 and in Argentina on 30 
August 2002. 
A new application was filed in the following countries: Canada and Brazil. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 24 February 2003. 
The Rapporteur's first Assessment Report was circulated to all CPMP members on 6 May 2003. 
The Co-Rapporteur's first Assessment Report was circulated to all CPMP members on 16 April 
2003. 
During  the  meeting  on  24-26  June  2003,  the  CPMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 26 June 2003. 
The  applicant  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on  11 
August 2003. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CPMP members on 22 September 2003. 
During the  CPMP meeting on 21-23 October 2003, the CPMP agreed on a list  of outstanding 
issues to be addressed in writing and/or in an oral explanation by the applicant. 
The  applicant submitted the responses  to the CPMP  list  of outstanding issues  on  3 November 
2003. 
The  Rapporteur  circulated  the  Assessment  Report  on  the  applicant’s  responses  to  the  list  of 
outstanding issues to all CPMP members on  10 November 2003. 
The CPMP convened a Therapeutic Advisory Group meeting on 17 November 2003 to provide 
advice on the clinical aspects of Faslodex. 
During  the  meeting  on    18-20  November  2003,  the  CPMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to Faslodex on 20 November 2003. The applicant provided 
a letter of undertaking on the follow-up measures to be fulfilled post-authorisation. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 10 March 2004. 
1/1 
EMEA 2005 
 
 
 
 
 
 
 
 
 
